524715:BOM
Sun Pharmaceutical Industries Ltd
1.754,70 ₹
arrow_downward
−0,34%(−5,90) 1D
16. okt., 11:18:26 GMT +5.30 · INR
search
Vsi simboli
| Simbol | Cena | Sprememba | Odstotna sprememba |
|---|
insights_autoGeneriranje najpomembnejših vpogledov za 524715 …
Odpri
1.759,60 ₹
Visoka
1.764,40 ₹
Nizka
1.744,85 ₹
Tržna kapitalizacija
4,21 bil.
Povprečni promet
97,37 tis.
Promet
18,06 tis.
Dividenda
0,91 %
Četrtletna dividenda
4,00 ₹
Prvi trgovalni dan brez upravičenja do dividende
7. jul. 2026
Razmerje med ceno delnice in čistim dobičkom
34,79
52-tedenski najvišji tečaj
2.047,55 ₹
52-tedenski najnižji tečaj
1.583,60 ₹
Čisti dobiček na delnico
50,44 ₹
Št. izdanih delnic
0,00
Št. zaposlenih
47 tis.
Odpri
1.759,60 ₹
Visoka
1.764,40 ₹
Nizka
1.744,85 ₹
Tržna kapitalizacija
4,21 bil.
Povprečni promet
97,37 tis.
Promet
18,06 tis.
Dividenda
0,91 %
Četrtletna dividenda
4,00 ₹
Prvi trgovalni dan brez upravičenja do dividende
7. jul. 2026
Razmerje med ceno delnice in čistim dobičkom
34,79
52-tedenski najvišji tečaj
2.047,55 ₹
52-tedenski najnižji tečaj
1.583,60 ₹
Čisti dobiček na delnico
50,44 ₹
Št. izdanih delnic
0,00
Št. zaposlenih
47 tis.
Novice
Iz spletnih virov in novičarskih partnerjev
ad-hoc-news.de
·
pred 16 urami
Analyst consensus puts Sun Pharma stock at INR 2,180.00
Moneycontrol.com
·
pred 2 dnevoma
Sun Pharma: Tariff relief, innovation brighten growth outlook
ad-hoc-news.de
·
pred 2 dnevoma
Geojit raises target for Sun Pharma stock to INR 2,070.00
Profil
Sun Pharmaceutical Industries Limited is an Indian multinational pharmaceutical company headquartered in Mumbai. It manufactures and sells pharmaceutical formulations and active pharmaceutical ingredients in more than 100 countries. It is the largest pharmaceutical company in India and the fourth largest specialty generic pharmaceutical company in the world.
Around 70% of Sun Pharma’s revenue is generated from international markets. The US and India are the largest markets, accounting for over 60% of the company's turnover. Manufacturing is across 43 locations in India, the US, Asia, Africa, Australia and Europe. The products cater to therapeutic segments covering psychiatry, anti-infectives, neurology, cardiology, diabetology, gastroenterology, ophthalmology, nephrology, urology, dermatology, gynaecology, respiratory, oncology, dental and nutritionals. Its active pharmaceutical products include baricitinib, brivaracetam, and dapaglifozin. Wikipedia
Vizitka: Sun Pharmaceutical Industries Ltd
Generalni direktor-
Št. zaposlenih47 tis.
Ustanovljeno1983
SedežGoregaon East, Bombaj, Indija
Sektor-
Spletno mestosunpharma.com